FUJIFILM Diosynth Biotechnologies has announced continued expansion of its cell culture manufacturing capabilities with the addition of two 2000L single-use bioreactors. One each of these is being installed at the company’s sites in Research Triangle Park (RTP), NC, USA and Billingham, UK.
The new reactors will complement the range of vessels at both sites, adding further flexibility for customer requirements. Each site currently operates 1000L single-use bioreactors with 250L to 1,000L operating volumes, with an additional 200L single-use bioreactor in the UK, and a 2000L stainless steel train in RTP, which has been in place for a number of years manufacturing a range of products.
“The addition of these two new bioreactors will meet the demand we are seeing for a 2000L platform, and offer a cost-effective, low-risk route to market through ‘scaling-out’ from early phase to commercial manufacture”
says Mr. Steve Bagshaw, Chief Executive Officer, FUJIFILM Diosynth Biotechnologies. He adds “Being similar to our existing bioreactors means they will fit seamlessly into our facilities. Having identical single-use operations on both sides of the Atlantic offers our customers flexibility and easy access to global markets. Combined with the expertise of our process development scientists to produce high-titer cell lines, our focus on single-use bioreactor technology for cell culture processes is world class.”
The company has over 15 years’ cell culture manufacturing experience with significant single-use facility expansions in the last three years at both sites. The facilities have been inspected by key regulatory authorities and utilise both traditional platforms as well as the latest single-use technologies. The new 2000L bioreactors are expected to be operational by November 2014 in the US and in the UK in January 2015.
Mr. Bagshaw concluded “With these expansions, FUJIFILM Diosynth Biotechnologies is able to deliver a significantly enhanced, full life cycle ‘Gene to GMP’ service for our customers".
For enquiries on information in this media release, contact:
Bridget Hall, Communications Manager
Fujifilm Diosynth Biotechnologies
Tel : +44 (0)1642 367320
Cell: +44 (0)7796 938929
Email : bridget.hall(at)fujifilmdb(dot)com
About Fujifilm Diosynth Biotechnologies
FUJIFILM Diosynth Biotechnologies UK Limited is an industry leading biologics Contract Development and Manufacturing Organization. FUJIFILM Diosynth Biotechnologies has extensive experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules expressed in a wide array of microbial, mammalian, and insect systems. The company offers a comprehensive list of services from microbial and mammalian cell line development, including its proprietary pAVEway™ system, to process development, analytical development, clinical and commercial manufacturing. FUJIFILM Diosynth Biotechnologies is also located in Research Triangle Park, NC, USA as FUJIFILM Diosynth Biotechnologies U.S.A., Inc. Both sites have been FDA-approved for the production of commercial biologic products.
For more information, please visit: www.fujifilmdiosynth.com
About FUJIFILM Holdings Corporation
FUJIFILM Holdings Corporation, Tokyo, Japan brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies. In the year ended March 31, 2014, the company had global revenues of $23.7 billion, at an exchange rate of 103 yen to the dollar. Fujifilm is committed to environmental stewardship and good corporate citizenship.
For more information, please visit: www.fujifilmholdings.com